Evidence map›Paper›PMID 29922285›Full record

ArticleFrontiers in immunology2018

Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.

Anke Rietveld, Luuk L van den Hoogen, Nicola Bizzaro, Sofie L M Blokland, Cornelia Dähnrich, Jacques-Eric Gottenberg, Gunnar Houen, Nora Johannsen, Thomas Mandl, Alain Meyer and 7 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Uncovering the significance of expanded CD8Frontiers in immunology · 2023
    Article
  15. Article
  16. Article
  17. Inclusion Body Myositis and Neoplasia: A Narrative Review.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Article
  20. Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 5 countries.

Anke RietveldDepartment of Neurology, Center for Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
Luuk L van den HoogenLaboratory of Translational Immunology, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Nicola BizzaroLaboratorio di Patologia Clinica, Ospedale San Antonio, Azienda Sanitaria Universitaria Integrata di Udine, Tolmezzo, Italy.
Sofie L M BloklandLaboratory of Translational Immunology, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Cornelia DähnrichInstitute for Experimental Immunology, Euroimmun AG, Lübeck, Germany.
Jacques-Eric GottenbergService de physiologie et d'explorations fonctionnelles, Service de rhumatologie, Centre de référence des maladies auto-immunes rares and Fédération de médecine translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France.
Gunnar HouenDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark.
Nora JohannsenInstitute for Experimental Immunology, Euroimmun AG, Lübeck, Germany.
Thomas MandlDepartment of Clinical Sciences Malmö, Lund University, Malmö, Sweden and Department of Rheumatology, Skåne University Hospital, Malmö, Sweden.
Alain MeyerService de physiologie et d'explorations fonctionnelles, Service de rhumatologie, Centre de référence des maladies auto-immunes rares and Fédération de médecine translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France.
Christoffer T NielsenCopenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Disease, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Peter OlssonDepartment of Clinical Sciences Malmö, Lund University, Malmö, Sweden and Department of Rheumatology, Skåne University Hospital, Malmö, Sweden.
Joel van RoonLaboratory of Translational Immunology, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Wolfgang SchlumbergerInstitute for Experimental Immunology, Euroimmun AG, Lübeck, Germany.
Baziel G M van EngelenDepartment of Neurology, Center for Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
Christiaan G J SarisDepartment of Neurology, Center for Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
Ger J M PruijnDepartment of Biomolecular Chemistry, Radboud Institute for Molecular Life Sciences and Institute for Molecules and Materials, Radboud University, Nijmegen, Netherlands.
Euroimmun Medizinische Labordiagnostika (Germany) · DERadboud University Medical Center · NLRadboud University Nijmegen · NLUniversité de Strasbourg · FRUtrecht University · NLCopenhagen University Hospital · DKLund University · SESkåne University Hospital · SEStatens Serum Institut · DKUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Autoantibodies to cytosolic 5'-nucleotidase 1A (cN-1A; NT5C1A) have a high specificity when differentiating sporadic inclusion body myositis from polymyositis and dermatomyositis. In primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE) anti-cN-1A autoantibodies can be detected as well. However, various frequencies of anti-cN-1A reactivity have been reported in SLE and pSS, which may at least in part be explained by the different assays used. Here, we determined the occurrence of anti-cN-1A reactivity in a large number of patients with pSS and SLE using one standardized ELISA. Methods: Sera from pSS ( Results: Anti-cN-1A autoantibodies were found on average in 12% of pSS patients, with varying frequencies among the different cohorts (range: 7-19%). In SLE patients, the anti-cN-1A positivity on average was 10% (range: 6-21%). No relationship was found between anti-cN-1A reactivity and the presence or absence of anti-Ro52, anti-nucleosome, and anti-dsDNA reactivity in both pSS and SLE. No relationship between anti-cN-1A reactivity and duration of disease at the moment of serum sampling and the duration of serum storage was observed. The frequency of muscular symptoms or viral infections did not differ between anti-cN-1A-positive and -negative patients. In both disease groups anti-cN-1A-positive patients suffered more often from other autoimmune diseases than the anti-cN-1A-negative patients (15 versus 5% ( Conclusion: Our results confirm the relatively frequent occurrence of anti-cN-1A in pSS and SLE patients and the variation in anti-cN-1A reactivity between independent groups of these patients. The explanation for this variation remains elusive. The correlation between anti-cN-1A reactivity and polyautoimmunity should be evaluated in future studies. We conclude that anti-cN-1A should be classified as a myositis-associated-, not as a myositis-specific-autoantibody based on its frequent presence in SLE and pSS.

Indexed as

5'-NucleotidaseAntibodies, AntinuclearAutoantibodiesAutoimmunityCohort StudiesCytosolFemaleHumansLupus Erythematosus, SystemicMaleMyositisNetherlandsPrevalenceRibonucleoproteinsSjogren's SyndromeSS-A Antigen5'-NucleotidaseAntibodies, AntinuclearAutoantibodiesRibonucleoproteinsSS-A Antigenanti-cN-1AautoantibodiesCytosolic 5′-nucleotidase 1Ainclusion body myositisNT5C1ASjögren’s syndromesystemic lupus erythematosus

Identifiers

PMID29922285
PMCPMC5996144
OpenAlexW2805613838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.